2 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow SARS-CoV2 Infection: new trials by email Literature Review of SARS-CoV2 Infection trials Research Report on SARS-CoV2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 / Phase 3 | Terminated | NEAT ID Foundation | 28 | 2022-10-27 | 2025-05-02 |
| Outpatient Treatment With Anti-Coronavirus Immunoglobulin Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo - COVID, SARS-CoV2 Infection | Phase 3 | Terminated | University of Minnesota | 741 | 2021-08-06 | 2026-08-13 |
COVID-19 (2) · Coronavirus Infections (1)
Coronaviridae Infections (2) · Infections (2) · Lung Diseases (2) · Nidovirales Infections (2) · Pneumonia (2) · Pneumonia, Viral (2) · RNA Virus Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Virus Diseases (2) · Coronavirus Infections (1)
HIV hyperimmune globulin (1) · fostamatinib (1)
NEAT ID Foundation (1) · University of Minnesota (1)
Spain (2) · Argentina (1) · Australia (1) · Brazil (1) · Denmark (1) · Germany (1) · Greece (1) · Italy (1) · Malaysia (1) · Mexico (1) · Peru (1) · South Africa (1) · Thailand (1) · Uganda (1) · Ukraine (1)
Anton Pozniak, Prof (1) · Cavan Reilly, PhD (1)